Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients
NCT ID: NCT04223427
Last Updated: 2026-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
19 participants
INTERVENTIONAL
2020-01-14
2025-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area
NCT01782638
Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait
NCT06994728
DBS of the MLR for Gait and Balance Disorders in PD Patients
NCT02931097
Combined Deep Brain Stimulation in Parkinson's Disease
NCT05415774
Effect of Deep Brain Stimulation on Neuropsychiatric Fluctuations in Patients With Parkinson's Disease
NCT04608123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single ring STN-DBS
The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
Directional and single ring STN-DBS on gait
Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days
* Surgery for STN-DBS electrodes implantation
* Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product
* Intraoperative electrophysiological recordings
* Intraoperative clinical evaluation
* Intraoperative identification of the electrodes and final position with X-Ray
* Post-operative 3D helical TDM without iode injection
* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery
* Placement of the neurostimulator (5 days after surgery)
* Acute testing of STN-DBS for first parameters setting programming
Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.
Directional and single ring STN-DBS on gait (M7)
Directional STN-DBS
The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
Directional and single ring STN-DBS on gait
Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days
* Surgery for STN-DBS electrodes implantation
* Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product
* Intraoperative electrophysiological recordings
* Intraoperative clinical evaluation
* Intraoperative identification of the electrodes and final position with X-Ray
* Post-operative 3D helical TDM without iode injection
* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery
* Placement of the neurostimulator (5 days after surgery)
* Acute testing of STN-DBS for first parameters setting programming
Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.
Directional and single ring STN-DBS on gait (M7)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Directional and single ring STN-DBS on gait
Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days
* Surgery for STN-DBS electrodes implantation
* Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product
* Intraoperative electrophysiological recordings
* Intraoperative clinical evaluation
* Intraoperative identification of the electrodes and final position with X-Ray
* Post-operative 3D helical TDM without iode injection
* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery
* Placement of the neurostimulator (5 days after surgery)
* Acute testing of STN-DBS for first parameters setting programming
Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.
Directional and single ring STN-DBS on gait (M7)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of Parkinson's Disease; as defined by the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria
4. Freezing of gait in the OFF-dopa condition with item 2.13 of the MDS-UPDRS \> 0 in usual life;
5. Patient having read and understood the information letter and signed the Informed Consent Form
6. Patient affiliated with, or beneficiary of a social security category
7. Stability of others medical disorders or that do not interfere with the research protocol.
8. Woman of childbearing potential with effective contraception according to WHO definition (estrogen-progestin or intra-uterine device or tubal ligation) since at least 3 months (negative urinary pregnancy test at inclusion)
Exclusion Criteria
2. Dementia (MMS \<24/30)
3. Contraindication to research MRI (without contrast product) such as claustrophobia, metallic splinters in the eyes, ferromagnetic foreign bodies close to nerve structures, cardiac, ORL and neurological devices not MRI compatible, wearing of osteosynthseis equipment prior to 1980, metal prostheses, bypass valves ventriculoperitoneal neurosurgery, tattoos containing iron particles…
4. Contraindication to surgery: hemostasis trouble, anticoagulants or antiagregants treatment, ongoing infection
5. Hypersensitivity to contrasts agents
6. Persons under guardianship, tutorship or any other administrative or judicial measure of deprivation of rights and liberty
7. Subject at the time of exclusion from other biomedical research or participating in any other biomedical research or therapeutic trial
8. Pregnant or parturient or lactating woman or lack of proven and effective contraception according to WHO definition (estrogen-progestin or intra-uterine device or tubal ligation) (for women of childbearing age)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de ROUEN
Rouen, France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018/0427/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.